Twist Bioscience CORP Form 4 insider transactions

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 1,693 shares of common stock to cover tax withholding obligations related to RSU vesting.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,085 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience CEO Emily M. Leproust reported a non-discretionary sale of 7,205 common shares to cover tax withholding obligations related to vested restricted stock units.

Twist Bioscience SVP of Human Resources, Paula Green, sold 1,465 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience Senior VP Dennis Cho sold 844 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Twist Bioscience's SVP of Human Resources, Paula Green, reported the sale of 39,404 shares of common stock under a Rule 10b5-1 plan.

Twist Bioscience CFO Adam Laponis executed a planned sale of 7,000 common shares at $50 each, reducing his direct holdings.

Twist Bioscience's SVP, Chief Legal Officer, Dennis Cho, sold 5,000 shares of common stock for $49.93 per share under a pre-arranged 10b5-1 trading plan.

Twist Bioscience Chief Accounting Officer Robert F. Werner gifted 2,000 shares of common stock to a charitable organization.

Twist Bioscience Corp Director Keith Crandell was granted 5,095 shares of common stock as an annual equity award, vesting in 2026.

Twist Bioscience Director Katryn Blake acquired 5,095 shares of common stock through an annual equity award, bringing her total beneficial ownership to 19,448 shares.

A Twist Bioscience director reported the acquisition of shares from an equity award and a subsequent 'sell to cover' transaction for tax liabilities.

Twist Bioscience's President and COO, Patrick John Finn, sold 2,705 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Dennis Cho, SVP and Chief Legal Officer of Twist Bioscience, sold 1,099 shares to cover tax withholding obligations related to RSU vesting.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, reported sales of company common stock totaling 7,175 shares in early February 2026.

Twist Bioscience SVP of Human Resources, Paula Green, sold 1,194 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's President and COO, Patrick John Finn, sold 2,390 shares of common stock at $44.908 per share to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 3,000 shares of common stock for $40 per share under a pre-arranged 10b5-1 trading plan.

Patrick John Finn, President and COO of Twist Bioscience Corp., executed a pre-arranged plan to exercise stock options and sell 23,279 shares of common stock.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,738 shares of common stock at $35.261 per share to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's SVP of Human Resources, Paula Green, sold 273 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Dennis Cho, SVP and Chief Legal Officer of Twist Bioscience, sold 324 shares of common stock to cover tax withholding obligations related to RSU vesting.

Twist Bioscience CEO Emily M. Leproust sold 1,605 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

A Twist Bioscience executive sold 398 shares of common stock at $32.878 per share to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience CEO Emily M. Leproust sold 2,255 shares of common stock at $32.878 per share to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's SVP of Human Resources, Paula Green, sold 877 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 230 shares of common stock to cover tax withholding obligations related to RSU vesting.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Twist Bioscience's Chief Legal Officer, Dennis Cho, sold 757 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's President and COO, Patrick John Finn, sold 1,776 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.